Transplant strategies for idiopathic myelofibrosis

Seminars in Hematology

Volumn 41, Issue 2 SUPPL. 3, 2004, Pages 23-29

  McCarty, John M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANABOLIC AGENT; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DANAZOL; ERYTHROPOIETIN; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; HYDROXYUREA; IMATINIB; MELPHALAN; OXYMETHOLONE; THALIDOMIDE;

AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLONAL VARIATION; DISEASE COURSE; EXTRAMEDULLARY HEMATOPOIESIS; HEMOGLOBIN DETERMINATION; HUMAN; KARYOTYPE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PALLIATIVE THERAPY; PANCYTOPENIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; SPLENECTOMY; SPLENOMEGALY; STEM CELL TRANSPLANTATION; SYMPTOMATOLOGY; THROMBOCYTHEMIA; WHOLE BODY RADIATION;

EID: 2442651407     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2004.02.009     Document Type: Article

References (65)

1. Tefferi A: Myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255-1265, 2000
2. Pearson TC, Messinezy M, Westwood N, Green AR, Bench AJ, Green AR, et al: A polycythemia vera updated: Diagnosis, pathobiology, and treatment. Hematology (Am Soc Hematol Educ Program) 51-68, 2000
3. Navone R, Colombano MT: Histopathological trephine biopsy findings in cases of 'dry tap' bone marrow aspirations. Appl Pathol 2:264-271, 1984
4. Willemin A: Radiography of breast cancers. J Gynecol Obstet Biol Reprod (Paris) 4:153-161, 1975 (suppl 2)
5. Rudorf I, Seidel R: Bone involvement in chronic myelocytic leukemia. Z Gesamte Inn Med 35:830-831, 1980
6. Paydas S, Ergin M, Baslamisli F, et al: Bone marrow necrosis: Clinicopathologic analysis of 20 cases and review of the literature. Am J Hematol 70:300-305, 2002
7. Mazieres B, Jung M, Bouteiller G, et al: Marrow scintigraphy in Paget's disease of bone (author's transl). Nouv Presse Med 7:2947-2948, 1978
8. De Pauw GA, Dermaut LR, Johansson CB, Martens G: A histomorphometric analysis of heavily loaded and non-loaded implants. Int J Oral Maxillofac Implants 17:405-412, 2002
9. Adams JA, Barrett AJ, Beard J, McCarthy DM: Primary polycythaemia, essential thrombocythaemia and myelofibrosis-Three facets of a single disease process? Acta Haematol 79:33-37, 1988
10. Juvonen E: Megakaryocyte colony formation in chronic myeloid leukemia and myelofibrosis. Leuk Res 12:751-756, 1988
11. Moliterno AR, Hankins WD, Spivak JL: Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 338:572-580, 1998
12. Goerttler P, Dorner E, Kutti J, Moliterno AR, Spivak JL, Pahl HL: Quantification of c-Mp1 protein expression and PRV-1 mRNA levels distinguish four distinct subpopulations of patients with ET. Blood 100:797a, 2002 (abstr)
13. Wang JC, Hashmi G: Elevated thrombopoietin levels in patients with myelofibrosis may not be due to enhanced production of thrombopoietin by bone marrow. Leuk Res 27:13-17, 2003
14. Tefferi A, Lasho TL, Wolanskyj AP, Mesa RA: Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood 2003 [Epub ahead of print]
15. Thiele J, Kvasnicka HM, Zankovich R, Diehl V: Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis. Ann Hematol 80:160-165, 2001
16. Schnuelle P, Waldherr R, Lehmann KJ, et al: Idiopathic myelofibrosis with extramedullary hematopoiesis in the kidneys. Clin Nephrol 52:256-262, 1999
17. Weinstein IM: Idiopathic myelofibrosis: Historical review, diagnosis and management. Blood Rev 5:98-104, 1991
18. Reilly JT: Idiopathic myelofibrosis: Pathogenesis, natural history and management. Blood Rev 11:233-242, 1997
19. Michiels JJ, Kutti J, Stark P, et al: Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential mega-karyocytic granulocytic metaplasia and myelofibrosis. Neth J Med 54:46-62, 1999
20. Dameshek W: Some speculations on the myeloproliferative syndromes. Blood 6:372-375, 1951
21. Jacobson RJ, Salo A, Fialkow PJ: Agnogenic myeloid metaplasia: A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 51:189-194, 1978
22. Reilly JT, Wilson G, Barnett D, Watmore A, Potter A: Karyotypic and ras gene mutational analysis in idiopathic myelofibrosis. Br J Haematol 88:575-581, 1994
23. Partanen S, Ruutu T, Vuopio P: Circulating haematopoietic progenitors in myelofibrosis. Scand J Haematol 29:325-330, 1982
24. + progenitor cells in idiopathic (primary) myelofibrosis: A comparative quantification between spleen and bone marrow tissue. Ann Hematol 81:86-89, 2002
25. + cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia. Eur J Haematol 68: 189-193, 2002
26. Thiele J, Kvasnicka HM, Fischer R, Diehl V: Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: A concise update. Leuk Lymphoma 24:463-481, 1997
27. Kieran MW, Perkins AC, Orkin SH, Zon LI: Thrombopoietin rescues in vitro erythroid colony formation from mouse embryos lacking the erythropoietin receptor. Proc Natl Acad Sci USA 93:9126-9131, 1996
28. Matsumura I, Kawasaki A, Tanaka H, et al: Biologic significance of GATA-1 activities in Ras-mediated megakaryocytic differentiation of hematopoietic cell lines. Blood 96:2440-2450, 2000
29. Bousse-Kerdiles MC, Martyre MC: Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis. Pathol Biol (Paris) 49:153-157, 2001
30. Giraudier S, Chagraoui H, Komura E, et al: Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. Blood 100:2932-2940, 2002
31. Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E: Idiopathic myelofibrosis: Initial features, evolutive patterns and survival in a series of 106 patients. Med Clin (Barc) 109:651-655, 1997
32. Garcia-Manero G, Schuster SJ, Patrick H, Martinez J: Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol 60:130-135, 1999
33. Andrieux J, Demory JL, Morel P, et al: Frequency of structural abnormalities of the long arm of chromosome 12 in myelofibrosis with myeloid metaplasia. Cancer Genet Cytogenet 137:68-71, 2002
34. Reilly JT: Cytogenetic and molecular genetic aspects of idiopathic myelofibrosis. Acta Haematol 108:113-119, 2002
35. Dupriez B, Morel P, Demory JL, et al: Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system. Blood 88:1013-1018, 1996
36. Cervantes F, Barosi G, DemoryJL, et al: Myelofibrosis with myeloid metaplasia in young individuals: Disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 102:684-690, 1998
37. Sagaster V, Jager E, Weltermann A, et al: Circulating hematopoietic progenitor cells predict survival in patients with myelofibrosis with myeloid metaplasia. Haematologica 88: 1204-1212, 2003
38. Hast R, Engstedt L, Jameson S, et al: Oxymetholone treatment in myelofibrosis. Blut 37:19-26, 1978
39. Barosi G, Grossi A, Comotti B, Musto P, Gamba G, Marchetti M: Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 114:78-83, 2001
40. Merup M, Kutti J, Birgergard G, et al: Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Med Oncol 19:79-86, 2002
41. Damaj G, Lefrere F, Canioni D, et al: Remission of transformed myelodysplastic syndrome with fibrosis after danazol therapy: Eur J Haematol 68:233-235, 2002
42. Bourantas KL, Tsiara S, Christou L, et al: A Combination therapy with recombinant human erythropoietin, interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in idiopathic myelofibrosis. Acta Haematol 96:79-82, 1996
43. Hasselbalch HC, Bjerrum OW, Jensen BA, et al: Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. Am J Hematol 74:238-242, 2003
44. Benbassat J, Gilon D, Penchas S: The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia. Am J Hematol 33:128-135, 1990
45. Silverstein MN, ReMine WH: Splenectomy in myeloid metaplasia. Blood 53:515-518, 1979
46. Elliott MA, Chen MG, Silverstein MN, Tefferi A: Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 103: 505-511, 1998
47. Manoharan A: Management of myelofibrosis with intermittent hydroxyurea. Br J Haematol 77:252-254, 1991
48. Barosi G, Liberato LN, Costa A, et al: Induction and maintenance alpha-interferon therapy in myelofibrosis with myeloid metaplasia. Eur J Haematol 52:12-14, 1990 (suppl)
49. Gilbert HS: Long term treatment of myeloproliferative disease with interferon-alpha-2b: Feasibility and efficacy. Cancer 83: 1205-1213, 1998
50. Petti MC, Latagliata R, Spadea T, et al: Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 116:576-581, 2002
51. Deeg HJ, Appelbaum FR: Stem-cell transplantation for myelofibrosis. N Engl J Med 344:775-776, 2001
52. Singhal S, Powles R, Treleaven J, Pollard C, Lumley H, Mehta J: Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplant 16:743-746, 1995
53. Soll E, Massumoto C, Clift RA, et al: Relevance of marrow fibrosis in bone marrow transplantation: A retrospective analysis of engraftment. Blood 86:4667-4673, 1995
54. Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R: Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol 98:1010-1016, 1997
55. Guardiola P, Esperou H, Cazals-Hatem D, et al: Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. French Society of Bone Marrow Transplantation. Br J Haematol 98:1004-1009, 1997
56. Guardiola P, Anderson JE, Bandini G, et al: Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study. Blood 93:2831-2838, 1999
57. Rajantie J, Sale GE, Deeg HJ, et al: Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradio-therapy and allogeneic bone marrow transplantation. Blood 67:1693-1697, 1986
58. Cervantes F: Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: An update anno 2000. Pathol Biol (Paris) 49:148-152, 2001
59. Deeg HJ, Gooley TA, Flowers ME, et al: Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102: 3912-3918, 2003
60. Anderson JE, Tefferi A, Craig F, et al: Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood 98:586-593, 2001
61. Devine SM, Hoffman R, Verma A, et al: Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 99:2255-2258, 2002
62. Tanner ML, Hoh CK, Bashey A, et al: FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia. Bone Marrow Transplant 32:581-585, 2003
63. Hessling J, Kroger N, Werner M, et al: Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 119:769-772, 2002
64. Li Z, Gooley T, Applebaum FR, Deeg HJ: Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood 97:2180-2181, 2001
65. Li Z, Deeg HJ: Pros and cons of splenectomy in patients with myelofibrosis undergoing stem cell transplantation. Leukemia 15:465-467, 2001